Morgan Stanley’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $13.7K | Sell |
|
|||||
|
2024
Q4 | $44.3K | Sell |
|
|||||
|
2024
Q3 | $75.4K | Sell |
|
|||||
|
2024
Q2 | $274K | Buy |
|
|||||
|
2024
Q1 | $320K | Sell |
|
|||||
|
2023
Q4 | $360K | Buy |
|
|||||
|
2023
Q3 | $38.5K | Hold |
|
|||||
|
2023
Q2 | $45.4K | Sell |
|
|||||
|
2023
Q1 | $48.4K | Sell |
|
|||||
|
2022
Q4 | $67.2K | Hold |
|
|||||
|
2022
Q3 | $72K | Hold |
|
|||||
|
2022
Q2 | $74K | Sell |
|
|||||
|
2022
Q1 | $104K | Buy |
|
|||||
|
2021
Q4 | $112K | Sell |
|
|||||
|
2021
Q3 | $193K | Hold |
|
|||||
|
2021
Q2 | $203K | Buy |
|
|||||
|
2021
Q1 | $118K | Buy |
|
|||||
|
2020
Q4 | $119K | Sell |
|
|||||
|
2020
Q3 | $127K | Buy |
|
|||||
|
2020
Q2 | $115K | Sell |
|
|||||
|
2020
Q1 | $207K | Sell |
|
|||||
|
2019
Q4 | $1.01M | Buy |
|
|||||
|
2019
Q3 | $759K | Buy |
|
|||||
|
2019
Q2 | $194K | Hold |
|
|||||
|
2019
Q1 | $193K | Sell |
|
|||||
|
2018
Q4 | $859K | Sell |
|
|||||
|
2018
Q3 | $2.24M | Sell |
|
|||||
|
2018
Q2 | $2.42M | Buy |
|
|||||
|
2018
Q1 | $188K | Buy |
|
|||||
|
2017
Q4 | $5K | Buy |
|
|||||
|
2017
Q2 | – | Sell |
|
|||||
|
2017
Q1 | $2K | Buy |
|